- Home
- WLYB vs HRMY Comparison
WLYB vs HRMY Comparison
Compare WLYB & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- HRMY
- Stock Information
- Founded
- WLYB 1807
- HRMY 2017
- Country
- WLYB United States
- HRMY United States
- Employees
- WLYB N/A
- HRMY N/A
- Industry
- WLYB Books
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- HRMY Health Care
- Exchange
- WLYB Nasdaq
- HRMY Nasdaq
- Market Cap
- WLYB 2.0B
- HRMY 1.8B
- IPO Year
- WLYB N/A
- HRMY 2020
- Fundamental
- Price
- WLYB $39.94
- HRMY $36.63
- Analyst Decision
- WLYB
- HRMY Strong Buy
- Analyst Count
- WLYB 0
- HRMY 9
- Target Price
- WLYB N/A
- HRMY $55.33
- AVG Volume (30 Days)
- WLYB 116.0
- HRMY 608.8K
- Earning Date
- WLYB 09-04-2025
- HRMY 08-05-2025
- Dividend Yield
- WLYB 3.54%
- HRMY N/A
- EPS Growth
- WLYB N/A
- HRMY 58.41
- EPS
- WLYB 1.53
- HRMY 3.10
- Revenue
- WLYB $1,677,609,000.00
- HRMY $772,527,000.00
- Revenue This Year
- WLYB $1.45
- HRMY $20.45
- Revenue Next Year
- WLYB $2.70
- HRMY $17.32
- P/E Ratio
- WLYB $25.55
- HRMY $11.79
- Revenue Growth
- WLYB N/A
- HRMY 17.74
- 52 Week Low
- WLYB $37.27
- HRMY $26.47
- 52 Week High
- WLYB $52.90
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- WLYB 39.96
- HRMY 58.40
- Support Level
- WLYB $41.30
- HRMY $32.64
- Resistance Level
- WLYB $42.70
- HRMY $36.74
- Average True Range (ATR)
- WLYB 0.00
- HRMY 1.25
- MACD
- WLYB 0.09
- HRMY 0.02
- Stochastic Oscillator
- WLYB 100.00
- HRMY 77.08
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.